Each test are MOLECULAR TESTS to detecting genetic material of the Covid-19 virus. The test is considered a RAPID test and results will be given to the patient within the same day of testing. The target population for this test is patients with Covid-19 Symptoms within the first 7 days of symptom onset. This test is not FDA approved. The test is available under an emergency access mechanism called an Emergency Use Authorization (EAU).
ID NOW uses isothermal technology, proprietary enzymes and constant temperature control to achieve the fastest available RNA amplification. This proven molecular system greatly reduces the time for results, allowing healthcare providers to make patient care decisions sooner.
The Accula SARS-CoV-2 Test accelerates PCR virus detection using our proprietary Oscillating Amplification Reaction (Oscar) PCR technology that enables shortened thermocycling times and faster PCR completion without the need for costly thermal cycler hardware and optical detection systems used in laboratory-based qPCR. Because the test can be administered, run, and interpreted in one place, time-to-results is reduced to 30 minutes—often while the subject waits. This makes the Accula System a practical tool for screening people prior to medical procedures, travel, or at the entrance to a concert or sporting event.
As of 2/14/21 all people traveling into Canada require a Nucleic Acid Amplification test, such as the Abbott ID Now with confirmation of a negative result. Please click link for more information on traveling to Canada.
Both test are on the lists of tests that are approved for individuals entering Canada. Please click the link below to follow all instructions required for crossing the border into Canada.